SB 699551

Pricing Availability   Qty
说明: Selective 5-ht5a antagonist
化学名: N-[2-(Dimethylamino)ethyl]-N-[[4'-[[(2-phenylethyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]cyclopentanepropanamide dihydrochloride
纯度: ≥99% (HPLC)
说明书
引用文献
评论
文献 (2)

生物活性 for SB 699551

SB 699551 is a selective 5-ht5a receptor antagonist (pKi values are 8.3, < 6.0, < 6.0, < 6.0, < 5.5 and < 5.5 for 5-ht5a, 5-HT1B/D, 5-HT2A, 5-HT2C, 5-HT1A and 5-HT7 receptors respectively).

许可信息

Sold for research purposes under agreement from GlaxoSmithKline

技术数据 for SB 699551

分子量 584.66
公式 C34H45N3O.2HCl
储存 Store at +4°C
纯度 ≥99% (HPLC)
CAS Number 864741-95-7
PubChem ID 11983346
InChI Key QJMKBIHLMPTYTI-UHFFFAOYSA-N
Smiles O=C(CCC4CCCC4)N(CCN(C)C)CC(C=C2)=CC=C2C1=CC=C(CNCCC3=CC=CC=C3)C=C1.Cl.Cl

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for SB 699551

溶剂 最高浓度 mg/mL 最高浓度 mM
溶解性
DMSO 14.62 25
ethanol 5.85 10

制备储备液 for SB 699551

以下数据基于产品分子量 584.66。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

选择批次从而根据批次分子量重新计算:
浓度/溶剂体积/质量 1 mg 5 mg 10 mg
0.25 mM 6.84 mL 34.21 mL 68.42 mL
1.25 mM 1.37 mL 6.84 mL 13.68 mL
2.5 mM 0.68 mL 3.42 mL 6.84 mL
12.5 mM 0.14 mL 0.68 mL 1.37 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

产品说明书 for SB 699551

分析证书/产品说明书
选择另一批次:

参考文献 for SB 699551

参考文献是支持产品生物活性的出版物。

Thomas et al (2006) SB-69951-A (3-cyclopentyl-N-[2-(dimethylamino)ethyl]-N-[(4'-{[(2-phenylethyl)amino]methyl}-4-biphenylyl)methyl]propanamide dihydrochloride), a novel 5-ht5A receptor-selective antagonist, enhances 5-HT neuronal function: evidence for an auto Neuropharmacology 51 566 PMID: 16846620

Thomas (2006) 5-ht5A receptors as a therapeutic target. Pharmacol.Ther. 111 707 PMID: 16516972

Corbett et al (2005) Discovery of a potent and selective 5-ht5A receptor antagonist by high-throughput chemistry. Bioorg.Med.Chem.letts. 15 4014 PMID: 16002289


If you know of a relevant reference for SB 699551, please let us know.

按标靶查看相关产品

按产品操作查看相关产品

查看全部 5-ht5 Receptor Antagonists

关键词: SB 699551, SB 699551 supplier, Selective, 5-ht5A, antagonists, Serotonin, Receptors, 5-Hydroxytryptamine, SB699551, GlaxoSmithKline, GSK, 5-ht5, 3188, Tocris Bioscience

篇 SB 699551 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 SB 699551 的引用文献。 您是否知道使用了 Tocris SB 699551 的优秀论文? 请告知我们.

SB 699551 的评论

目前没有该产品的评论。 Be the first to review SB 699551 and earn rewards!

Have you used SB 699551?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


5-HT Receptors Scientific Review

5-HT Receptors Scientific Review

Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.